Completed OBSERVATIONAL NCT05633108

A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders

A Retrospective Observational Study Based on the French National Health Insurance Database to Describe Antipsychotic Monotherapy and Polypharmacy Use, Including Loxapac, and to Investigate Their Association With Psychiatric Rehospitalization in Patients With Psychotic Disorders

Sponsor: Eisai Co., Ltd.

Conditions Psychotic Disorders

Interventions No Intervention

Updated 6 times since 2022 Last updated: Nov 16, 2023 Started: Mar 30, 2023 Primary completion: Sep 30, 2023 Completion: Sep 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05633108, this observational or N/A phase trial focuses on Psychotic Disorders and remains completed. Sponsored by Eisai Co., Ltd., it has been updated 6 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2023 — Jul 2024 [monthly]

Completed

Status: Active Not Recruiting → Completed
Nov 2023 — Dec 2023 [monthly]

Active Not Recruiting
Jul 2023 — Nov 2023 [monthly]

Active Not Recruiting

Status: Not Yet Recruiting → Active Not Recruiting

▶ Show 1 earlier version

Dec 2022 — Jul 2023 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Co., Ltd.

Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hatfield, United Kingdom